Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|13|16|1845-1857

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.13, Iss.16, 2006-07, pp. : 1845-1857

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy

By  

Current Drug Targets, Vol. 11, Iss. 8, 2010-01 ,pp. : 1000-1017

Bentham Science Publishers

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders

By  

Current Medicinal Chemistry, Vol. 16, Iss. 22, 2009-08 ,pp. : 2890-2898

Bentham Science Publishers

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor Receptor as Target for Advanced Non-Small Cell Lung Cancer Therapy

By  

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 865-874

Bentham Science Publishers

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor (VEGF) and the VEGF Soluble Receptor-1 (sFlt-1) in Chorionic Villus Tissue from Chinese Women with Early Recurrent Spontaneous Abortion

By Pang L-H   Li M-J   Li M-Q   Yang D-M   Shi L  

The Journal of International Medical Research, Vol. 39, Iss. 3, 2011-05 ,pp. : 830-837

Field House Publishing

Access to resources Recommend Favorite

Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?

By Bruce David   Tan Peng H  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1413-1434

Informa Healthcare

Access to resources Recommend Favorite